恒瑞医药(600276.SH)：HRS9531注射液、HRS-5817注射液临床试验获批准

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection and HRS-5817 injection [1] Group 1 - The approval includes conducting clinical trials of HRS9531 injection in combination with HRS-5817 injection for adult patients who are obese or overweight [1]